____________________________________________________________________________________________ LabLogic Systems
which combine diagnostics and therapy . Radioactivity has been used for many years to diagnose various diseases via scans , but in fields like radiotherapy , it can be used to attack various diseases and kill cancer cells . However , radioactivity can also have negative effects on the body . As a result , the industry is working on theranostics by developing specific types of radioactive materials that can target diseases without causing collateral damage . Thanks to our reputation , we have been approached by various institutions around the world to partner with them on research in theranostics . For instance , we are working with the University of York on a funded Knowledge Transfer Project ( KTP ) involving targeted alpha therapies ( TAT ). Additionally , King ’ s College London has asked us to collaborate on a similar project through the Engineering and Physical Sciences Research Council , and we are part of a large European consortium to develop QC techniques and associated technology for
these novel materials over the next five years . Overall , I believe that aside from the markets we are already strong in , theranostics presents a significant potential growth area for us ,” Richard enlightens .
In closing our conversation , Richard reveals the factors contributing to LabLogic ’ s 21 percent increase in its annual turnover since 2023 . “ I believe it was partly driven by the marketplace ’ s continued confidence in our products . Although the pharmaceutical industry is vast , drug development and nuclear medicine are niche markets . By being in those markets for so long and working for the same type of clients over the years , we have instilled a high level of trust in our company . We do not merely sell products to our customers ; we are partners who help them develop the next generation of products they may need ,” he ends . ■
lablogic . com
manufacturing-today . com 77